Ze‐Xiao Lin

998 total citations
23 papers, 693 citations indexed

About

Ze‐Xiao Lin is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Ze‐Xiao Lin has authored 23 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 9 papers in Epidemiology and 7 papers in Molecular Biology. Recurrent topics in Ze‐Xiao Lin's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Ze‐Xiao Lin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Ze‐Xiao Lin collaborates with scholars based in China and Hong Kong. Ze‐Xiao Lin's co-authors include Weicheng Liang, Qi Zhang, Xingyang Xue, Wei Qi, Zhijie Feng, Shitao Rao, Cuicui Xiao, Dan‐Yun Ruan, Xing Li and Xiaokun Ma and has published in prestigious journals such as Journal of Clinical Oncology, Gut and Annals of the Rheumatic Diseases.

In The Last Decade

Ze‐Xiao Lin

22 papers receiving 686 citations

Peers

Countries citing papers authored by Ze‐Xiao Lin

Since Specialization

Citations

This map shows the geographic impact of Ze‐Xiao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze‐Xiao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze‐Xiao Lin more than expected).

Fields of papers citing papers by Ze‐Xiao Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ze‐Xiao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze‐Xiao Lin. The network helps show where Ze‐Xiao Lin may publish in the future.

Co-authorship network of co-authors of Ze‐Xiao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Ze‐Xiao Lin. A scholar is included among the top collaborators of Ze‐Xiao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ze‐Xiao Lin. Ze‐Xiao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tepotinib interaction triggers a slight effect on the overall stability of hemoglobin protein, reinforcing the potential suitability as a drug candidate against gastric cancer 2025 ·International Journal of Biological Macromolecules ·Dong‐Hao Wu, Ze‐Xiao Lin, Jing‐Yun Wen, (unknown)	0
2	Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review 2022 ·Frontiers in Oncology ·Wei Li, Ze‐Xiao Lin, Sidong Xie, Dan‐Yun Ruan, Wen G. Jiang, Yueli Cui, Sisi Liu, Tiantian Wang, Zhan‐Hong Chen, Qu Lin	3
3	Analysis of the lncRNA–miRNA–mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC 2022 ·Frontiers in Genetics ·(unknown), Jufeng Zhang, (unknown), (unknown), Ze‐Xiao Lin, Weicheng Liang, Xingyang Xue	12
4	Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus 2020 ·Gut ·Weicheng Liang, Zhijie Feng, Shitao Rao, Cuicui Xiao, Xingyang Xue, Ze‐Xiao Lin, Qi Zhang, Wei Qi	272
5	mRNA modification orchestrates cancer stem cell fate decisions 2020 ·Molecular Cancer ·Weicheng Liang, Ze‐Xiao Lin, Cong Du, Dongbo Qiu, Qi Zhang	37
6	circNFATC3 sponges miR‐548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression 2020 ·Journal of Cellular Physiology ·Changchang Jia, Zhicheng Yao, Ze‐Xiao Lin, Liyun Zhao, Xiurong Cai, Shaohong Chen, Meihai Deng, (unknown)	21
7	THU0385 SAFETY OF TOFACITINIB THERAPY IN HBSAG CARRIERS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY 2020 ·Annals of the Rheumatic Diseases ·Lin Fang, Ze‐Xiao Lin, Zetao Liao, O. Jin, Jun Gu	1
8	Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer 2019 ·Cancer Biotherapy and Radiopharmaceuticals ·Xiaokun Ma, Liyuan Zou, Xing Li, Zhan‐Hong Chen, Ze‐Xiao Lin, Xiang-yuan Wu	10
9	Validation and ranking of seven staging systems of hepatocellular carcinoma 2017 ·Oncology Letters ·Zhan‐Hong Chen, (unknown), (unknown), Xing Li, Dong‐Hao Wu, Jing‐Yun Wen, Jie Chen, Dan‐Yun Ruan, Qu Lin, Min Dong, Wei Li, Tiantian Wang, Ze‐Xiao Lin, Xiaokun Ma, Xiangyuan Wu, Rui‐Hua Xu	21
10	Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies 2017 ·Journal of Cancer ·Xiurong Cai, Zhan‐Hong Chen, Jie Chen, Xiaokun Ma, (unknown), Tiantian Wang, Xiangwei Chen, Dong‐Hao Wu, (unknown), Xing Li, Qu Lin, Jing‐Yun Wen, Dan‐Yun Ruan, Ze‐Xiao Lin, Min Dong, Xiangyuan Wu	35
11	Endoplasmic reticulum stress induced LOX‐1⁺CD15⁺ polymorphonuclear myeloid‐derived suppressor cells in hepatocellular carcinoma 2017 ·Immunology ·Nan Jiang, Yan‐Fang Xing, Bo Hu, Jianxin Tang, (unknown), (unknown), Dan‐Yun Ruan, (unknown), (unknown), Xiaokun Ma, Jie Chen, Xiurong Cai, Ze‐Xiao Lin, Xiangyuan Wu, Xing Li	94
12	Comparison of a new prognostic system and other three current staging systems in predicting the survival rate of patients with HBV-associated advanced hepatocellular carcinoma. 2016 ·Journal of Clinical Oncology ·(unknown), Zhan‐Hong Chen, Qu Lin, Min Dong, Xing Li, (unknown), Xiaokun Ma, Wei Li, Dan‐Yun Ruan, Ze‐Xiao Lin, Jie Chen, Tiantian Wang, Xiang-yuan Wu	2
13	Female cancer patients’ awareness and role in family-based medical decision making mode in Confucian area. 2016 ·Journal of Clinical Oncology ·Xing Li, Yan‐Fang Xing, (unknown), (unknown), Min Dong, Xiaokun Ma, Zhan‐Hong Chen, (unknown), Dan‐Yun Ruan, Ze‐Xiao Lin, Tian-tian Wang, Dong‐Hao Wu, Xiangyuan Wu	1
14	Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization 2015 ·Tumor Biology ·(unknown), Xing Li, (unknown), Xiaokun Ma, Dong‐Hao Wu, Mingsheng Huang, Zhan‐Hong Chen, Jie Chen, Min Dong, Wei Li, Tiantian Wang, Dan‐Yun Ruan, Ze‐Xiao Lin, Xiang Zhong, Yan‐Fang Xing, Jing‐Yun Wen, Xiangyuan Wu, Qu Lin	5
15	Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma 2015 ·Tumor Biology ·(unknown), Zhan‐Hong Chen, Xiaokun Ma, Xing Li, Dong‐Hao Wu, Jie Chen, Min Dong, Wei Li, Tiantian Wang, Dan‐Yun Ruan, Ze‐Xiao Lin, Jing‐Yun Wen, Qu Lin, Changchang Jia, Xiangyuan Wu	5
16	MicroRNA-34a-5p enhances sensitivity to chemotherapy by targeting AXL in hepatocellular carcinoma MHCC-97L cells 2015 ·Oncology Letters ·(unknown), (unknown), (unknown), Tiantian Wang, Xing Li, Min Dong, Qu Lin, (unknown), (unknown), Wei Li, Ze‐Xiao Lin, Dan‐Yun Ruan, Jie Chen, Dong‐Hao Wu, Wei Liu, Yan Tai, (unknown), (unknown), Qi Zhang	25
17	Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma 2014 ·Tumor Biology ·Dong‐Hao Wu, Changchang Jia, Jie Chen, Ze‐Xiao Lin, Dan‐Yun Ruan, Xing Li, Qu Lin, (unknown), Xiaokun Ma, Xiang‐Bo Wan, Na Cheng, Zhan‐Hong Chen, Yan‐Fang Xing, (unknown), Jing‐Yun Wen	77
18	Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer 2013 ·Journal of Chemotherapy ·Zhi‐Yong Wu, (unknown), Ze‐Xiao Lin, (unknown), Lan Zhou, (unknown)	3
19	An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study 2012 ·Tumor Biology ·Xiangyuan Wu, Xing Li, Zhan‐Hong Chen, Jing‐Yun Wen, Qu Lin, Yan‐Fang Xing, Min Dong, Wei Li, Tiantian Wang, Jie Chen, Ze‐Xiao Lin, Xiang‐Bo Wan, Dan‐Yun Ruan, Xiaokun Ma	7
20	Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience 2011 ·Leukemia & lymphoma ·Huiqiang Huang, Ze‐Xiao Lin, (unknown), Qingqing Cai, Zhongjun Xia, Wenqi Jiang	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact